A
150.36
-0.84 (-0.56%)
| Previous Close | 151.20 |
| Open | 152.13 |
| Volume | 359,541 |
| Avg. Volume (3M) | 542,834 |
| Market Cap | 7,580,044,800 |
| Price / Earnings (Forward) | 303.03 |
| Price / Sales | 15.51 |
| Price / Book | 120.91 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | -64.39% |
| Operating Margin (TTM) | -45.67% |
| Diluted EPS (TTM) | -5.76 |
| Quarterly Revenue Growth (YOY) | 62.00% |
| Total Debt/Equity (MRQ) | 397.02% |
| Current Ratio (MRQ) | 2.03 |
| Operating Cash Flow (TTM) | -118.32 M |
| Levered Free Cash Flow (TTM) | -20.98 M |
| Return on Assets (TTM) | -26.17% |
| Return on Equity (TTM) | -282.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Axsome Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 4.0 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.80 |
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 16.31% |
| % Held by Institutions | 76.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 248.00 (UBS, 64.94%) | Buy |
| Median | 201.00 (33.68%) | |
| Low | 169.00 (Needham, 12.40%) | Buy |
| Average | 202.38 (34.60%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 159.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 13 Jan 2026 | 193.00 (28.36%) | Buy | 174.98 |
| 04 Nov 2025 | 157.00 (4.42%) | Buy | 134.93 | |
| Morgan Stanley | 08 Jan 2026 | 204.00 (35.67%) | Hold | 167.55 |
| 04 Nov 2025 | 196.00 (30.35%) | Buy | 134.93 | |
| UBS | 06 Jan 2026 | 248.00 (64.94%) | Buy | 171.88 |
| HC Wainwright & Co. | 05 Jan 2026 | 200.00 (33.01%) | Buy | 171.49 |
| 04 Nov 2025 | 185.00 (23.04%) | Buy | 134.93 | |
| Needham | 31 Dec 2025 | 169.00 (12.40%) | Buy | 182.64 |
| 04 Nov 2025 | 154.00 (2.42%) | Buy | 134.93 | |
| Mizuho | 06 Nov 2025 | 202.00 (34.34%) | Buy | 139.41 |
| Guggenheim | 04 Nov 2025 | 205.00 (36.34%) | Buy | 134.93 |
| RBC Capital | 04 Nov 2025 | 198.00 (31.68%) | Buy | 134.93 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SAAD MARK E | - | 182.64 | -37,577 | -6,863,063 |
| TABUTEAU HERRIOT | - | 171.35 | -139,414 | -23,894,584 |
| Aggregate Net Quantity | -176,991 | |||
| Aggregate Net Value ($) | -30,757,647 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 174.18 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Officer | 07 Jan 2026 | Automatic sell (-) | 31,261 | 170.69 | 5,335,940 |
| TABUTEAU HERRIOT | Officer | 07 Jan 2026 | Option execute | 31,261 | - | - |
| TABUTEAU HERRIOT | Officer | 06 Jan 2026 | Automatic sell (-) | 29,450 | 171.88 | 5,061,866 |
| TABUTEAU HERRIOT | Officer | 06 Jan 2026 | Option execute | 29,450 | - | - |
| TABUTEAU HERRIOT | Officer | 05 Jan 2026 | Automatic sell (-) | 78,703 | 171.49 | 13,496,777 |
| TABUTEAU HERRIOT | Officer | 05 Jan 2026 | Option execute | 78,703 | - | - |
| SAAD MARK E | Director | 31 Dec 2025 | Automatic sell (-) | 37,577 | 182.64 | 6,863,063 |
| SAAD MARK E | Director | 31 Dec 2025 | Option execute | 37,577 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |